Berlin Life Sciences Hiring: Why €1 Billion in Biotech Investment Has Not Solved the Talent Problem
Berlin's biotech cluster attracted nearly €900 million in venture capital in 2024, yet more than half of all cell therapy process development roles posted in the city remained unfilled after 90 days. That disconnect is not a temporary imbalance. It is the defining feature of a market where capital has moved faster than human capital can follow.
The city now hosts over 340 biotech companies and 160 medtech firms, anchored by one of Europe's most productive research triangles: the Charité, the Max Delbrück Center, and the Berlin Institute of Health. Together, these institutions generated 1,447 invention disclosures and 155 patent applications in 2023 alone. The science is there. The infrastructure to commercialise it is there. The people required to bridge the two are not, at least not in sufficient numbers or in the right specialisms.
What follows is an analysis of the forces reshaping Berlin's life sciences sector, the specific roles and skills where hiring has stalled, and what senior leaders need to understand before making their next executive appointment in this market. The gap between what Berlin's biotech cluster produces and the talent available to commercialise it has become the single largest constraint on the sector's growth. Understanding where that gap sits, and why conventional approaches have failed to close it, is the starting point for any organisation trying to hire effectively here.
The Research Engine Is Running. The Talent Pipeline Is Not.
Berlin's life sciences ecosystem is built on a research foundation that few European cities can match. The Charité alone employs over 21,000 people, including 5,800 academic staff, and runs an annual research budget of €386 million. The Max Delbrück Center adds another 1,600 staff and €154 million in budget, specialising in cardiovascular research and single-cell genomics. The Berlin Institute of Health, operating as the translational bridge between the two, contributes 1,200 staff and €98 million.
This is not a cluster struggling for ideas. It is a cluster struggling to turn ideas into products and products into revenue. Only 12% of Berlin-based life sciences seed-stage companies progressed to Series A within 24 months in 2023. Compare that to 19% in Munich and 23% in Cambridge, UK, according to Dealroom's European Biotech Report. The gap is not primarily financial. It is human. The roles required to drive commercialisation, regulatory submission, and manufacturing scale-up are precisely the roles Berlin's biotech and medtech employers cannot fill.
The "Series A valley of death" is well documented. Early-stage VC availability for Berlin biotech fell 62% from its 2021 peak. The average seed round sits at €2.1 million, while Series A thresholds now start above €15 million. But even as capital contracted through 2023 and 2024, specialised lab space vacancy tightened from 2.1% to 0.8%. This is the first analytical tension that matters: the funding winter did not ease the infrastructure constraint. Companies that survived the capital squeeze still could not find space to operate, and still could not find the people to staff the space they had.
The investment environment is now recovering. EY's Germany Venture Capital Barometer projects Berlin biotech funding to reach €1.1 to €1.3 billion in 2026, supported by European Central Bank rate reductions and a returning appetite for growth equity. New lab supply from the Matryoshka District in Adlershof and expansions at Campus Berlin-Buch will add approximately 18,000 square metres in the second half of 2026. Capital is returning. Space is slowly expanding. But the talent pipeline that connects both to commercial outcomes has not kept pace with either.
The Skills Mismatch Hiding Inside the Headline Numbers
Berlin's life sciences job postings rose 18% year-over-year in 2024. Medtech roles climbed 24%. Biotech roles rose 14%. On aggregate, those numbers suggest a healthy, growing market. They conceal a more troubling reality.
Bayer's Layoffs Created a False Signal
Bayer AG's 2024 global restructuring eliminated approximately 260 positions in Berlin, primarily in traditional pharmaceutical marketing and small-molecule chemistry. According to Germany's Federal Employment Agency, aggregate unemployment among laboratory scientists in Berlin edged up to 2.8%. To an outside observer, this might suggest a loosening of supply. It is the opposite.
The positions Bayer cut were in disciplines where supply already exceeded demand. The positions the rest of the ecosystem is trying to fill sit in entirely different specialisms. Cell therapy process development, computational biology, advanced therapy medicinal product manufacturing, and IVDR regulatory affairs bear almost no overlap with the roles that were made redundant. The result is simultaneous unemployment in one category and acute, persistent scarcity in another, within the same city.
Where the 90-Day Vacancy Wall Sits
Three categories now define the hardest-to-fill segment of Berlin's life sciences market. Process development scientists with cell therapy expertise lead the list: 52% of posted positions remain open after 90 days. Bioinformatics and computational biology roles carry a 45% vacancy rate for candidates with a PhD and five or more years of experience. Quality assurance and regulatory affairs roles specifically requiring IVDR expertise have seen days-to-fill increase by 38% since 2022.
The average time-to-fill for senior technical roles across Berlin's life sciences market has extended to 127 days, up from 89 days in 2021. That 38-day increase represents more than a scheduling inconvenience. For a startup with an 18-month runway, it can mean the difference between completing a regulatory submission and missing a filing window. For an established manufacturer expanding a production line, it means delayed revenue on committed capital expenditure.
This is not a shortage that more job advertising will fix. It is a shortage of professionals who sit at the intersection of disciplines that barely existed a decade ago: compliance officers who understand IVDR and AI conformity assessment simultaneously, computational biologists who can work inside a GMP-regulated cell line development environment, process engineers whose experience covers viral vector manufacturing from bench to commercial scale. You cannot recruit experience that does not yet exist in sufficient quantity. The talent market is catching up to the science, but it has not arrived yet.
The Compensation Equation That Keeps Berlin on the Back Foot
Berlin's life sciences compensation has risen materially. It has not risen enough to close the gap with the markets competing for the same candidates. This is the structural challenge that sits beneath every search in the city.
At the executive level, a VP of R&D or Chief Scientific Officer in Berlin commands total cash compensation of €220,000 to €320,000. In Munich, equivalent roles carry a 12% to 18% premium. In Basel or Zurich, the premium reaches 35% to 45%, compounded by a lower Swiss tax burden and proximity to Roche and Novartis decision centres. For executive-level leadership in biotech, Berlin's cost-of-living advantage, which historically offset the salary gap, is eroding. Residential rents in the city rose 14% in 2024, reducing the differential with Munich and narrowing the gap with London.
The Signing Bonus Arms Race
The compensation gap has produced predictable behaviour. According to Handelsblatt's reporting on the medtech labour market, Siemens Healthineers' Berlin diagnostics division offered €25,000 to €35,000 signing bonuses and 20% to 25% base salary premiums to recruit Senior Regulatory Affairs Managers with EU MDR technical documentation experience from competitors including Roche Diagnostics and Becton Dickinson during 2023 and 2024. These are not retention packages. They are extraction packages, designed to move passive candidates out of stable roles.
This pattern is not isolated. A typical search for a CMC Director with gene therapy viral vector experience in Berlin ran 9 to 14 months in 2024, compared to 4 to 6 months for an equivalent small-molecule role. One mid-stage gene therapy firm, according to HLB Life Sciences Recruitment's market analysis, retained a search consultant for 11 months before securing a candidate from a Basel-based competitor, paying a 35% salary premium above the Berlin market median.
Equity Dilution Is Compounding the Problem
The compensation challenge goes beyond base salary and bonuses. Down rounds now represent 34% of Berlin biotech financing events, compared to 8% in 2021. Each down round dilutes the equity packages that early and mid-stage companies use to bridge the compensation gap with large pharma and Swiss employers. A candidate weighing a move to a Berlin Series A biotech is not just comparing salary figures. They are assessing whether the equity component, often 0.5% to 2.5% at VP level, will retain its value through the next financing round. In a market where one in three rounds is a down round, that assessment increasingly favours the stability of a Munich pharma role or a Basel contract. This dynamic explains why the hidden 80% of passive candidates in this market require a fundamentally different approach to engagement.
Regulatory Complexity Is Rewriting Every Hiring Requirement
The EU regulatory environment for medtech and diagnostics has transformed since 2021, and Berlin sits at the intersection of every major change. The MDR and IVDR transitions have extended time-to-CE-mark by 8 to 14 months for novel medtech devices, according to BVMed's Economic Report. The EU AI Act adds a further layer: medtech AI products now face additional conformity assessments costing €400,000 to €800,000 and adding 6 to 9 months to market entry.
The Notified Body Bottleneck
Only 12 notified bodies are currently designated for EU IVDR certification. The result is a 12- to 18-month queue for Berlin diagnostic startups seeking certification. This is not a staffing challenge at the regulatory body level that any single company can solve. It is a systemic constraint that changes the profile of every regulatory affairs professional a Berlin medtech firm needs to hire. The days when regulatory expertise meant understanding one framework are over. A regulatory affairs director in Berlin now needs fluency across MDR, IVDR, EU AI Act conformity assessment, and BfArM interactions for combined drug-device products. The pool of candidates with that breadth of experience is vanishingly small.
Compliance costs have increased by an average of €2.3 million per PMA-equivalent for Berlin-based medtech manufacturers. These costs are not one-off. They are recurring, which means the regulatory team that manages them is not a project hire but a permanent capability requirement. Firms that treated MDR compliance as a temporary workstream are now discovering they need standing regulatory capacity that Berlin's labour market cannot supply quickly.
For organisations trying to build a talent pipeline in this regulatory environment, the implication is clear: the search must start earlier, reach further geographically, and present a proposition that addresses more than compensation. Candidates with the right regulatory profile are contacted three to five times monthly by recruiters. They are not short of options. The question is why they would choose Berlin over Amsterdam, where the European Medicines Agency creates a concentration of regulatory expertise, or Basel, where the salary premium removes the conversation about money entirely.
The AI-Bio Convergence: Berlin's Opportunity and Its Deepest Talent Gap
Berlin is positioning itself as a European hub for AI-drug discovery convergence. The city is projected to capture 15% to 18% of German AI-biotech funding, supported by the presence of Merantix Momentum and the MDC's AI-focused Berlin Institute for Medical Systems Biology. Siemens Healthineers employs approximately 3,800 staff in Berlin, including R&D teams working on AI applications for diagnostic imaging and the VARO surgical robotics platform. The institutional foundation for AI-driven innovation in life sciences is substantial.
The talent to staff that foundation is among the hardest to find anywhere in Europe. AI and machine learning drug discovery scientists sit at the exact intersection of computational expertise and biological domain knowledge. According to StepStone's analysis, 75% of candidates qualified for these roles are passive, making conventional job advertising almost entirely ineffective. The competition is not coming from other biotech firms. It is coming from Google Health, Microsoft, and the broader technology sector, where compensation packages and equity structures dwarf what a Berlin biotech startup can offer.
The ProBioGen example illustrates the challenge. Before its acquisition by Samsung Biologics, ProBioGen publicly cited difficulties scaling its Berlin AI-driven cell line development platform due to computational biology scarcity. According to Fierce Biotech Europe's reporting, the firm's search for a Head of Computational Biology extended by seven months, ultimately recruiting from ETH Zurich with a relocation package exceeding €50,000.
Here is the original synthesis this data supports: the investment in AI-bio convergence has not reduced workforce requirements. It has replaced one category of scientist with another that does not yet exist in sufficient numbers. Capital allocated to AI-drug discovery platforms moved faster than the universities and training programmes that produce the computational biologists to run them. Every euro invested in AI capability creates demand for a professional profile that the European education system produces at a fraction of the required volume. Berlin's institutions are among the best positioned to train this next generation, but the current cohort of experienced practitioners is too small for the current demand, and the demand is accelerating.
The Geographic Pull: Where Berlin Loses Talent and Why
Berlin's talent losses follow predictable patterns, but the patterns differ by seniority and specialism. Understanding the direction of flow is essential for any organisation designing a compensation and retention strategy for this market.
The Munich Migration
Munich remains the primary domestic competitor. It offers 12% to 18% salary premiums, a larger concentration of established pharma employers including Roche Diagnostics and Merck KGaA, and the Martinsried biotech campus, which provides the kind of specialised lab infrastructure that Berlin's 0.8% vacancy rate makes almost impossible to secure. According to LinkedIn's Talent Migration data, senior Berlin biotech executives frequently move to Munich for VP-level and above roles at established pharmaceutical companies. The reverse flow exists, but it is driven by a different motivation: founders and early-stage leaders move to Berlin for the startup ecosystem, the incubator infrastructure, and the venture capital network that Munich's more corporate environment does not replicate.
The Swiss Premium
Switzerland accounts for 18% of Berlin-based PhD-level medicinal chemists and ATMP specialists who leave Germany, according to BIO Deutschland's Talent Retention Survey. The pull is straightforward: 35% to 45% salary premiums, lower personal tax rates, and direct access to Roche and Novartis headquarters. For a mid-career scientist earning €120,000 in Berlin, the equivalent Basel role offers €165,000 to €175,000 before tax advantages. The proposition is difficult to counter with equity in a startup facing a down round.
The Boston Brain Drain
Approximately 8% of Berlin biotech C-level executives relocated to the Boston-Cambridge cluster between 2022 and 2024, according to the German Accelerator's tracking. The draw is not just compensation, though 60% to 80% premiums at current exchange rates are material. It is the depth of the venture capital ecosystem, faster FDA pathways compared to EMA, and a concentration of experienced leadership talent that Berlin cannot yet match. Berlin loses its most seasoned founders and commercial leaders to the market with the deepest pockets and the most developed support infrastructure.
For hiring leaders in Berlin, this means the competitive set for any senior role extends well beyond the city and well beyond Germany. A search conducted only within Berlin's borders will miss the candidates who have already left and the candidates in competitor geographies who might be persuaded to come. The reach of the search determines the quality of the shortlist.
What This Means for Organisations Hiring in Berlin Now
The Berlin life sciences market in 2026 presents a specific challenge that differs from a conventional tight labour market. In a conventional tight market, more money solves most problems. In Berlin's biotech and medtech cluster, the constraint is not willingness to pay. It is the existence of candidates with the right combination of skills at any price.
When 85% to 90% of qualified VP-level and C-suite candidates are passive, and when the remaining 10% to 15% who are actively looking generate a "candidate-rich, quality-poor" dynamic at mid-levels, the entire approach to executive hiring must change. Posting a role and waiting for applications reaches a fraction of the viable market. In specialisms like cell therapy CMC leadership or computational biology, it reaches close to zero qualified candidates.
The cost of a failed or prolonged executive search in this market compounds faster than in most sectors. A CMC Director vacancy does not just mean an empty desk. It means a clinical programme that cannot file, a manufacturing process that cannot scale, and a regulatory submission that misses its window. At a startup with an 18-month runway, every month of unfilled leadership directly reduces the probability of reaching the next financing milestone.
KiTalent's approach to this market is built on direct headhunting methodology designed specifically for environments where the candidates you need are not visible through conventional channels. AI-powered talent mapping identifies and engages the passive 85% to 90% of the qualified candidate pool, the professionals currently embedded in roles at Charité, Siemens Healthineers, MDC, and their European counterparts who will not respond to a job posting but will respond to a precise, well-positioned approach. Interview-ready candidates are presented within 7 to 10 days, with full pipeline transparency and weekly reporting.
In a market where the average senior technical search runs 127 days and the most critical roles take 9 to 14 months, the speed of engagement is not a convenience. It is the difference between securing the candidate and losing them to Basel, Munich, or Boston before the first interview.
For organisations competing for cell therapy, computational biology, and regulatory affairs leadership in Berlin's life sciences market, where the candidates who can drive your programmes forward are embedded in roles elsewhere and contacted by recruiters multiple times each month, speak with our executive search team about how we approach this market differently.
Frequently Asked Questions
What are the hardest life sciences roles to fill in Berlin in 2026?
Cell therapy process development scientists lead the list, with 52% of posted positions unfilled after 90 days. Bioinformatics and computational biology roles carry a 45% vacancy rate at senior levels. IVDR regulatory affairs specialists have seen days-to-fill increase 38% since 2022. The common thread is that these roles require combinations of skills, such as viral vector manufacturing with GMP experience, or deep learning with biological domain knowledge, that conventional pharmaceutical training does not produce. The shortage is not cyclical. It reflects a foundational gap between what the sector now needs and what the talent pipeline currently delivers.
How does Berlin life sciences compensation compare to Munich and Basel?
Berlin trails Munich by 12% to 18% and Switzerland by 35% to 45% at equivalent seniority levels. A VP of R&D in Berlin earns total cash compensation of €220,000 to €320,000. The same role in Basel commands €300,000 to €465,000 before tax advantages. Berlin's historical cost-of-living advantage has narrowed as residential rents rose 14% in 2024. Startups attempt to bridge the gap with equity, but with 34% of financing rounds now being down rounds, equity packages carry more risk and less perceived value than they did in 2021.
Why is lab space scarcity affecting hiring in Berlin's biotech sector?
Specialised wet-lab vacancy in Berlin sits at 0.8%, with rents of €28 to €32 per square metre per month now exceeding Munich for the first time. New lab facilities require 36 to 42 months to develop due to biological containment building code requirements. Companies unable to secure appropriate lab space cannot expand teams even when funding is available. This constraint persisted even during the funding contraction of 2022 to 2024, demonstrating that infrastructure scarcity, not capital scarcity, is the binding constraint on Berlin's biotech growth.
How can companies attract passive life sciences candidates in Berlin?
At VP and C-suite level, 85% to 90% of qualified candidates are passive. They are not reviewing job boards. They are being approached directly, often three to five times monthly by recruiters. Successful approaches require precise talent mapping to identify the right individuals, a compelling role proposition that addresses career trajectory alongside compensation, and speed of engagement that prevents competing offers from arriving first. KiTalent's AI-enhanced direct search methodology is designed for exactly this dynamic, reaching candidates in the passive majority and presenting them interview-ready within 7 to 10 days.
What regulatory changes are affecting medtech hiring in Berlin?
The MDR and IVDR transitions have added 8 to 14 months to CE-mark timelines for novel devices. The EU AI Act introduces further conformity assessments costing €400,000 to €800,000 for medtech AI products. Only 12 notified bodies are designated for IVDR certification, creating 12- to 18-month queues. These changes have made regulatory affairs professionals with cross-framework expertise among the most sought-after candidates in the market, and among the hardest to recruit given that Amsterdam and Basel compete aggressively for the same individuals.
What is the typical timeline for an executive search in Berlin's life sciences sector?
The average senior technical role in Berlin now takes 127 days to fill, up from 89 days in 2021. Specialised roles take considerably longer: CMC Directors with gene therapy experience face 9- to 14-month search timelines. These timelines reflect both the scarcity of qualified candidates and the complexity of the proposition required to move them. Firms using retained executive search approaches that access passive candidates directly and move with urgency consistently outperform organisations relying on job advertising and inbound applications in this market.
